Given the documented yet mechanistically incompletely understood anti-leukemic effects of these compounds (35), this finding suggests a novel and testable hypothesis: that targeting EXOSC2 may represent a previously unrecognized mechanism contributing to their efficacy in AML. Here, EXOSC2 is linked to acute myeloid leukemia.